HC Wainwright Cuts Corcept Therapeutics (NASDAQ:CORT) Price Target to $145.00

Corcept Therapeutics (NASDAQ:CORT) had its target price trimmed by HC Wainwright from $150.00 to $145.00 in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.32 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $1.29 EPS, FY2026 earnings at $3.56 EPS, FY2027 earnings at $7.33 EPS, FY2028 earnings at $10.47 EPS and FY2029 earnings at $12.96 EPS.

CORT has been the topic of several other reports. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. StockNews.com lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Truist Financial lifted their target price on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Finally, Piper Sandler upped their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a research report on Thursday, April 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $138.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $71.39 on Tuesday. The stock’s 50-day simple moving average is $66.58 and its two-hundred day simple moving average is $60.64. Corcept Therapeutics has a twelve month low of $25.35 and a twelve month high of $117.33. The firm has a market capitalization of $7.57 billion, a P/E ratio of 56.66 and a beta of 0.22. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $157.21 million for the quarter, compared to analysts’ expectations of $177.93 million. During the same period in the prior year, the business earned $0.25 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 7.1% compared to the same quarter last year. As a group, equities analysts anticipate that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider William Guyer sold 7,060 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $74.31, for a total value of $524,628.60. Following the completion of the sale, the insider now owns 5,487 shares in the company, valued at approximately $407,738.97. This trade represents a 56.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. Insiders have sold a total of 236,738 shares of company stock valued at $20,476,238 in the last quarter. Insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Kestra Investment Management LLC purchased a new stake in shares of Corcept Therapeutics in the 4th quarter worth about $27,000. MassMutual Private Wealth & Trust FSB boosted its position in Corcept Therapeutics by 102.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 313 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of Corcept Therapeutics by 1,150.8% during the 1st quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 679 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Corcept Therapeutics in the 4th quarter worth approximately $40,000. Finally, National Bank of Canada FI purchased a new position in shares of Corcept Therapeutics in the 4th quarter valued at approximately $42,000. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.